EPIX - ESSA Pharma Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.5000
0.0000 (0.00%)
At close: 2:59PM EST
Stock chart is not supported by your current browser
Previous Close2.5000
Open2.4700
Bid0.00 x 1000
Ask0.00 x 800
Day's Range2.4700 - 2.5900
52 Week Range0.1000 - 5.8300
Volume0
Avg. Volume5,182
Market Cap16.14M
Beta (3Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-3.80
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire28 days ago

    Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors
    PR Newswire2 months ago

    ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors

    HOUSTON and VANCOUVER, Oct. 22, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Otello Stampacchia, Ph.D., Founder and Managing Director of Omega Funds, a Boston-based biotech and medical device investment firm, to the Company's Board of Directors.  Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.

  • ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors
    CNW Group2 months ago

    ESSA Appoints Otello Stampacchia, PH.D., of Omega Funds to Board of Directors

    HOUSTON and VANCOUVER , Oct. 22, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Otello Stampacchia , Ph.D., Founder and Managing Director of Omega Funds, a Boston -based biotech and medical device investment firm, to the Company's Board of Directors.  Mr. Stampacchia was appointed pursuant to the terms of a nomination rights agreement between the Company and Omega Fund Management, LLC.

  • ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018
    PR Newswire3 months ago

    ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018

    HOUSTON and VANCOUVER, Aug. 29, 2018 /PRNewswire/ - ESSA Pharma Inc. (TSX-V: EPIX, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson, President and Chief Executive Officer, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright, in New York City on Wednesday, September 5th, at 5:05 PM Eastern Standard Time at the St. Regis Hotel in New York.

  • ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018
    CNW Group3 months ago

    ESSA Pharma to Present at 20th Annual Global Investment Conference In New York City September 4 - 6, 2018

    HOUSTON and VANCOUVER , Aug. 29, 2018 /CNW/ - ESSA Pharma Inc. (TSX-V: EPIX, NASDAQ: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that David R. Parkinson , President and Chief Executive Officer, will be presenting at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright, in New York City on Wednesday, September 5 th, at 5:05 PM Eastern Standard Time at the St. Regis Hotel in New York .

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018
    CNW Group4 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018
    PR Newswire4 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2018

    HOUSTON and VANCOUVER , Aug. 14, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies ...

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018
    CNW Group7 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2018

  • Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements
    CNW Group7 months ago

    Essa Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

    HOUSTON and VANCOUVER , May 10, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, Nasdaq: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that it received a notice from the Nasdaq Listing Qualifications Staff on May 10, 2018 notifying the Company that it regained compliance with the Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"). Accordingly, ESSA is in compliance with all applicable listing standards and its common stock will continue to be listed on the Nasdaq and the Nasdaq considers this matter closed.

  • ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018
    CNW Group8 months ago

    ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018

    ESSA to present at Bloom Burton & Co. Healthcare Investor Conference 2018

  • ESSA Pharma Inc. Announces Completion of Share Consolidation
    CNW Group8 months ago

    ESSA Pharma Inc. Announces Completion of Share Consolidation

    ESSA Pharma Inc. Announces Completion of Share Consolidation

  • ESSA Pharma Enhances R&D Capabilities with Two New Key Hires
    CNW Group8 months ago

    ESSA Pharma Enhances R&D Capabilities with Two New Key Hires

    HOUSTON and VANCOUVER , April 24, 2018 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on the development of novel small molecule drugs for the treatment of prostate cancer, announced today the appointments of Han-Jie Zhou , Ph.D., Vice President, Chemistry and Chemistry Manufacturing and Control, and Ronan Le Moigne , Ph.D., Senior Director, Preclinical. Dr. Zhou has more than 18 years of experience in oncology drug discovery and development including medicinal and process chemistry, drug metabolism and pharmacokinetics, chemistry manufacturing and control, project management, and global outsourcing.  Prior to joining ESSA, he was Vice President of Chemistry at Cleave Biosciences, Group Leader at Proteolix and Scientist at Cytokinetics.

  • ESSA Pharma Inc. Announces Share Consolidation
    CNW Group8 months ago

    ESSA Pharma Inc. Announces Share Consolidation

    ESSA Pharma Inc. Announces Share Consolidation

  • Does ESSA Pharma Inc (CVE:EPI) Go Up With The Market?
    Simply Wall St.8 months ago

    Does ESSA Pharma Inc (CVE:EPI) Go Up With The Market?

    For ESSA Pharma Inc’s (TSXV:EPI) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. EPI is exposedRead More...

  • ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
    PR Newswire8 months ago

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

    HOUSTON and VANCOUVER , March 28, 2018 /PRNewswire/ -   ESSA Pharma Inc. (" ESSA " or the " Company ") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused ...

  • ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
    CNW Group8 months ago

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

    ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

  • ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
    PR Newswire10 months ago

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

    HOUSTON and VANCOUVER, Feb. 23, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that on February 21, 2018 the board of directors of the Company ("Board") passed a resolution adopting a new stock option plan (the "New Option Plan") and a restricted share unit plan (the "RSU Plan"). On November 27, 2017, ESSA's common shares ("Common Shares") were delisted from the Toronto Stock Exchange and conditionally listed on the TSX Venture Exchange (the "TSXV"). As a condition to the listing of the Common Shares on the TSXV, the Company is required to adopt a stock option plan that complies with Policy 4.4 – Incentive Stock Options of the TSXV Corporate Finance Manual. In order to comply with this condition, the Board has approved the New Option Plan, which is a fixed number stock option plan that incorporates TSXV requirements and will replace the Company's existing option plan.

  • ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants
    CNW Group10 months ago

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

    ESSA Pharma Approves Stock Option Plan, RSU Plan, and Option Grants

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
    CNW Group10 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

  • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017
    PR Newswire10 months ago

    ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2017

    HOUSTON and VANCOUVER , Feb. 13, 2018 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies ...

  • ESSA to Present at Noble Capital Markets' NobleCon14
    CNW Group11 months ago

    ESSA to Present at Noble Capital Markets' NobleCon14

    ESSA to Present at Noble Capital Markets' NobleCon14

  • ESSA to Present at Noble Capital Markets' NobleCon14
    PR Newswire11 months ago

    ESSA to Present at Noble Capital Markets' NobleCon14

    Nasdaq: EPIX) ("ESSA" or the "Company") today announced that David R. Parkinson, President and Chief Executive Officer, will present at NobleCon14 - Noble Capital Markets' Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Monday January 29th at 1:30pm Eastern Standard Time.

  • ESSA Announces Management Team Change
    PR Newswire11 months ago

    ESSA Announces Management Team Change

    Nasdaq: EPIX) ("ESSA" or the "Company") announced today that  Frank Perabo, M.D., Ph.D., will depart ESSA as the Company's Chief Medical Officer to pursue other opportunities, effective January 31, 2018.  Dr. Perabo will continue to serve the Company in an advisory capacity, and as a member of ESSA's medical advisory committee. ESSA announced in September 2017, its intention to cease clinical development of EPI-506 and  utilize the results from the successfully completed Phase 1 proof of concept trial to expand the preclinical development program around more potent next-generation aniten molecules.  Within the next-generation program, the Company expects to file an Investigational New Drug filing and initiate a Phase 1 clinical trial of the selected next-generation molecule in the first quarter of 2019.  ESSA recently announced the completion of an approximately  US$26 million financing to fund preclinical and clinical development within its next-generation Aniten program.

  • ESSA Announces Management Team Change
    CNW Group11 months ago

    ESSA Announces Management Team Change

    ESSA Announces Management Team Change

  • ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule
    CNW Group11 months ago

    ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule

    ESSA expects 180-day extension to regain compliance with the Nasdaq Bid Price Rule